We intend to focus our efforts identifying businesses in technology, direct to consumer and FinTech industries. (Note: This new blank-check company is unusual in that its board chair, its CEO and its CFO are all women – at a time when most SPACs or blank-check companies are still run by men. This special-purpose acquisition company […]

We intend to search for a target business that provides critical resources and/or services to the technologies powering the 21st century industrial economy. Opportunities include, but are not limited to, suppliers or extractors of essential and scarce natural resources (such as lithium, nickel, aluminum, hydrogen, helium and cobalt), electrification and energy transition (such as fuel cells, […]

(Note: Leonardo DRS, Inc. withdrew its IPO plans in an SEC letter dated Sept. 29, 2022, noting the company decided not to proceed with the IPO, and had instead decided to enter into an all-stock merger with RADA Electronic Industries Ltd. Leonardo DRS had filed its S-1 for the IPO on Feb. 26, 2021. Its […]

Our mission is to build and enable the most trusted and efficient digital marketplaces for buying and selling used vehicles with transparency and comprehensive data that was previously unimaginable.  We provide a vibrant digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information to our customers. Our platform leverages […]

We are a clinical-stage biopharmaceutical company developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies to treat patients with cancer. We are advancing our lead TIL product candidate, ITIL-168, to treat advanced melanoma. We plan to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration and, […]

We are a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to […]

We are a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets. Our lead […]

Our mission is to build an IoT developer ecosystem and to enable everything to be smart.  We have pioneered a purpose-built IoT cloud platform that delivers a full suite of offerings, including Platform-as-a-Service (PaaS) and Software-as-a-Service (SaaS) to businesses and developers. IoT is changing the world. Our IoT PaaS offering enables businesses and developers to quickly and cost […]

We are a newly formed blank check company that will seek to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or assets, which we refer to throughout this prospectus as our initial business combination. To date, our efforts have been limited to organizational […]

We are a biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”), including rare genetic diseases and neurological disorders. We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small […]